Evaluation of the effect of premedication in controlling acute complications of intravenous immunoglobulin injectio
Phase 3
Recruiting
- Conditions
- premedication use for intravenous immunoglobulin administration.Adverse effect of immunoglobulinT50.Z15
- Registration Number
- IRCT20210206050268N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
All patients with a diagnosis of neurological disease, including myasthenia gravis, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), etc., who are candidates for IVIG will be included in the study.
Exclusion Criteria
The patient's unwillingness to participate in the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complications of intravenous immunoglobulin injection based on checklist. Timepoint: Evaluation of complications one and six hours after injection. Method of measurement: checklist.
- Secondary Outcome Measures
Name Time Method